|
CBX2 expression profile based on
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
| Comparison | Statistical significance |
| ER negative-vs-ER positive | 3.95098079075184E-05
|
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
| Comparison | Statistical significance |
| HER2 Negative-vs-HER2 Positive | 5.032070E-02 |
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
| Comparison | Statistical significance |
| PR Negative-vs-PR Positive | 1.036569E-04 |
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
| Comparison | Statistical significance |
| LN negative-vs-LN positive | 5.313313E-01 |
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
| Comparison | Statistical significance |
| Less than 50-vs-Greater than 50 | 1.232522E-01 |
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Grade 1-vs-Grade 2 |
5.287626E-01 |
| Grade 1-vs-Grade 3 |
1.72383416517869E-08 |
| Grade 2-vs-Grade 3 |
2.48428611200571E-08 |
|
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| T1-vs-T2 |
1.151212E-01 |
| T1-vs-T4 |
3.353234E-01 |
| T2-vs-T4 |
4.031713E-01 |
|
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Low-vs-Intermediate |
8.779032E-01 |
| Low-vs-High |
1.047758E-04 |
| Intermediate-vs-High |
1.077108E-04 |
|
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Low-vs-Intermediate |
4.428900E-01 |
| Low-vs-High |
4.423052E-03 |
| Intermediate-vs-High |
3.25085169408267E-06 |
|
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Luminal A-vs-Luminal B |
1.793702E-03 |
| Luminal A-vs-HER2 |
5.700782E-03 |
| Luminal A-vs-Basal |
1.33736163637341E-06 |
| Luminal B-vs-HER2 |
6.086265E-02 |
| Luminal B-vs-Basal |
3.662951187036E-05 |
| HER2-vs-Basal |
4.159694E-01 |
|
|
*
Please note that low number(<10) of samples considered.
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal like-vs-LumA |
8.695755E-02 |
| Normal like-vs-LumB |
5.662668E-01 |
| Normal like-vs-HER2 enriched |
1.630514E-03 |
| Normal like-vs-Basal like |
1.18985819304927E-05 |
| LumA-vs-LumB |
1.230091E-02 |
| LumA-vs-HER2 enriched |
1.881754E-04 |
| LumA-vs-Basal like |
7.11216560432393E-06 |
| LumB-vs-HER2 enriched |
3.584071E-03 |
| LumB-vs-Basal like |
1.57986140425657E-05 |
| HER2 enriched-vs-Basal like |
2.098146E-01 |
|
|
